175 related articles for article (PubMed ID: 9585867)
1. Eprosartan.
McClellan KJ; Balfour JA
Drugs; 1998 May; 55(5):713-8; discussion 719-20. PubMed ID: 9585867
[TBL] [Abstract][Full Text] [Related]
2. Eprosartan: a review of its use in the management of hypertension.
Plosker GL; Foster RH
Drugs; 2000 Jul; 60(1):177-201. PubMed ID: 10929934
[TBL] [Abstract][Full Text] [Related]
3. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
Levine B
Curr Med Res Opin; 2001; 17(1):8-17. PubMed ID: 11464450
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of eprosartan.
Weber M
Pharmacotherapy; 1999 Apr; 19(4 Pt 2):95S-101S. PubMed ID: 10213528
[TBL] [Abstract][Full Text] [Related]
5. Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension. Eprosartan Study Group.
Gradman AH; Gray J; Maggiacomo F; Punzi H; White WB
Clin Ther; 1999 Mar; 21(3):442-53. PubMed ID: 10321414
[TBL] [Abstract][Full Text] [Related]
6. Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. Eprosartan Study Group.
Elliott WJ
J Hum Hypertens; 1999 Jun; 13(6):413-7. PubMed ID: 10408592
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of eprosartan, a new angiotensin II receptor blocker.
Shusterman NH
Am Heart J; 1999 Sep; 138(3 Pt 2):238-45. PubMed ID: 10467219
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of eprosartan.
Gavras I; Gavras H
Pharmacotherapy; 1999 Apr; 19(4 Pt 2):102S-107S. PubMed ID: 10213529
[TBL] [Abstract][Full Text] [Related]
9. A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure, platelets, and endothelium function in patients with essential hypertension.
Leu HB; Charng MJ; Ding PY
Jpn Heart J; 2004 Jul; 45(4):623-35. PubMed ID: 15353873
[TBL] [Abstract][Full Text] [Related]
10. Eprosartan: a review of its use in the management of hypertension.
Robins GW; Scott LJ
Drugs; 2005; 65(16):2355-77. PubMed ID: 16266204
[TBL] [Abstract][Full Text] [Related]
11. Eprosartan: an angiotensin-II receptor antagonist for the management of hypertension.
Cheng-Lai A
Heart Dis; 2002; 4(1):54-9. PubMed ID: 11975834
[TBL] [Abstract][Full Text] [Related]
12. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension.
Delles C; Jacobi J; John S; Fleischmann I; Schmieder RE
Kidney Int; 2002 Apr; 61(4):1462-8. PubMed ID: 11918753
[TBL] [Abstract][Full Text] [Related]
13. Management of hypertension: the advent of a new angiotensin II receptor antagonist.
Hedner T
J Hypertens Suppl; 1999 Jun; 17(2):S21-5. PubMed ID: 10465063
[TBL] [Abstract][Full Text] [Related]
14. Eprosartan: a review of its use in hypertension.
Plosker GL
Drugs; 2009; 69(17):2477-99. PubMed ID: 19911859
[TBL] [Abstract][Full Text] [Related]
15. Antihypertensive effects and safety of eprosartan: a meta-analysis of randomized controlled trials.
Xu FY; Yang B; Shi D; Li H; Zou Z; Shi XY
Eur J Clin Pharmacol; 2012 Feb; 68(2):195-205. PubMed ID: 21881888
[TBL] [Abstract][Full Text] [Related]
16. Clinical profile of eprosartan.
Puig JG; López MA; Bueso TS; Bernardino JI; Jiménez RT;
Cardiovasc Drugs Ther; 2002 Dec; 16(6):543-9. PubMed ID: 12766389
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group.
Sega R
Blood Press; 1999; 8(2):114-21. PubMed ID: 10451039
[TBL] [Abstract][Full Text] [Related]
18. The clinical profile of the angiotensin II receptor blocker eprosartan.
Hedner T
J Hypertens Suppl; 2002 Jun; 20(5):S33-8. PubMed ID: 12184062
[TBL] [Abstract][Full Text] [Related]
19. A dose proportionality study of eprosartan in healthy male volunteers.
Chapelsky MC; Martin DE; Tenero DM; Ilson BE; Boike SC; Etheredge R; Jorkasky DK
J Clin Pharmacol; 1998 Jan; 38(1):34-9. PubMed ID: 9597557
[TBL] [Abstract][Full Text] [Related]
20. Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group.
Gavras I; Gavras H
Curr Med Res Opin; 1999; 15(1):15-24. PubMed ID: 10216807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
